托珠单抗治疗糖皮质激素抵抗性甲状腺眼病的疗效。
Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease.
机构信息
Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain.
Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain.
出版信息
Med Clin (Barc). 2023 Feb 10;160(3):113-117. doi: 10.1016/j.medcli.2022.05.007. Epub 2022 Sep 8.
INTRODUCTION
Thyroid eye disease (TED) is a complex and incompletely understood rare autoimmune disorder.
OBJECTIVES
To analyze the experience and the outcomes obtained with the use of intravenous tocilizumab in the treatment of TED.
METHODS
A retrospective analysis of adult patients diagnosed with active TED resistant to intravenous corticosteroids treated in a tertiary hospital between May 2012 and May 2021.
RESULTS
Eleven patients were included with a mean age of 52±12 (range 35-67) years. Nine patients were female and two were male. Patients received a median of 5±3.2 doses. Twenty out of twenty-four eyes achieved inactivation of TED at week 16. Proptosis response was achieved in 6/8 patients and diplopia response in 3/8 patients. The GO-QOL questionnaire showed clinically significant improvement in 9/11 patients. No serious adverse effects were reported during tocilizumab treatment. One patient required decompressive surgery 15 months after tocilizumab therapy.
CONCLUSION
The results obtained show that the use of tocilizumab in the treatment of this pathology can be a good alternative.
介绍
甲状腺眼病（TED）是一种复杂且尚未完全了解的罕见自身免疫性疾病。
目的
分析使用静脉注射托珠单抗治疗 TED 的经验和结果。
方法
对 2012 年 5 月至 2021 年 5 月在一家三级医院接受治疗的、对静脉注射皮质类固醇治疗有反应的活动性 TED 成年患者进行回顾性分析。
结果
纳入 11 例患者，平均年龄为 52±12 岁（范围 35-67 岁）。9 例为女性，2 例为男性。患者接受了中位数为 5±3.2 剂的治疗。24 只眼中有 20 只在第 16 周时 TED 活动度得到抑制。6/8 例患者的眼球突出度得到改善，3/8 例患者的复视得到改善。GO-QOL 问卷显示 11 例患者中有 9 例在临床方面有显著改善。在托珠单抗治疗期间未报告严重不良反应。1 例患者在托珠单抗治疗后 15 个月需要进行减压手术。
结论
结果表明，托珠单抗在该疾病的治疗中可能是一种很好的选择。
Zotero 插件